Risk Factors Analysis for Rapid In-Hospital Mortality among Covid-19 Patients in a Tertiary Care Hospital in Indonesia

Authors

  • Juwita Febriawati Department of Pulmonology and Respiratory Medicine Faculty of Medicine Universitas Brawijaya Malang
  • Ngakan Putu Parsama Putra Department of Pulmonology and Respiratory Medicine Faculty of Medicine Universitas Brawijaya Malang
  • Aditya Sri Listyoko Department of Pulmonology and Respiratory Medicine Faculty of Medicine Universitas Brawijaya Malang
  • Susanthy Djajalaksana Department of Pulmonology and Respiratory Medicine Faculty of Medicine Universitas Brawijaya Malang

Keywords:

Covid-19, CRP, PaO2/FiO2 ratio, procalcitonin, time of in-hospital mortality

Abstract

Systemic inflammation plays an important role in pathogenesis of Covid-19, especially in development of ARDS which is characterized by decrease of PaO2/FiO2 ratio. CRP and procalcitonin are inflammatory markers that are closely associated with severity and mortality of Covid-19. Although several studies have addressed benefit of CRP and procalcitonin as markers on Covid-19 severity, the benefit of these inflammatory markers for in-hospital mortality remain inadequately understood. The aim of this study was to analyze PaO2/FiO2 ratio,comorbidity,CRP,and procalcitonin as risk factors that affect time of in-hospital mortality Covid-19 patient. This was a retrospective observational cohort study of 250 Covid-19 patients who died during hospitalization and data was retrieved from medical record. Laboratory data was collected from three different times, including at time of admission,third day of hospital care,and before patient’s death. Data were analyzed using Chi square test,Mann Whitney test,Wilcoxon test, Friedman test, and binary logistic regresion. There were significant differences between CRP and procalcitonin at admission and time of in-hospital mortality (p<0.001; p=0.007). Binary logistic regression  analysis revealed significant relationship between CRP and time of in-hospital mortality with p=0.007. ROC curve showed optimal threshold of 11.75mg/L with sensitivity 72.3%; specificity 59.6%, RR 3.24(95% CI: 1.84-5.70). Significant changes were observed regarding PaO2/FiO2 ratio,CRP,and procalcitonin at admission as compared to before patient’s death with p<0.001;p=0.017;p<0.001 respectively. This study showed significant decrease of PaO2/FiO2 ratio, elevated CRP and procalcitonin at admission as compared to before patient’s death. The increase of CRP could serve as predictor for time of in-hospital mortality for Covid-19 patient.

Downloads

Download data is not yet available.

References

World Health Organization. WHO COVID-19 Dashboard. (Online) 2022. https://data.who.int/dashboards/Covid19/cases?n=c [accessed 15 January 2023].

Santus P, Radovanovic D, Saderi L, et al. Severity of Respiratory Failure at Admission and In-Hospital Mortality in Patients with COVID-19: A Prospective Observational Multicentre Study. BMJ Open. 2020; 10(10): 1-11.

Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine. 2020; 180(7): 934–943.

Grieco DL, Bongiovanni F, Chen L, et al. Respiratory Physiology of COVID-19-Induced Respiratory Failure Compared to ARDS of Other Etiologies. Critical Care. 2020; 24(1): 1-11.

Gao J, Zhong L, Wu M, et al. Risk Factors for Mortality in Critically Ill Patients with COVID-19: A Multicenter Retrospective Case-Control Study. BMC Infectious Diseases. 2021; 21(1): 1-8.

Dereli N, Babayigit M, Koç F, et al. Relationship Between Inflammatory Parameter and Mortality in Intensive Care Patients with COVID-19. Eastern Journal of Medicine. 2022; 27(1): 146–154.

Ullah W, Thalambedu N, Haq S, et al. Predictability of CRP and D-Dimer Levels for In-Hospital Outcomes and Mortality of COVID-19. Journal of Community Hospital Internal Medicine Perspectives. 2020; 10(5): 402–408.

Ahmadi-Abhari S, Luben RN, Wareham NJ, and Khaw KT. Seventeen Year Risk of All-Cause and Cause-Specific Mortality Associated with C-Reactive Protein, Fibrinogen and Leukocyte Count in Men and Women: The EPIC-Norfolk Study. Eurupean Journal of Epidemiology. 2013; 28(7): 541–550.

Liu F, Li L, Xu M, et al. Prognostic Value of Interleukin-6, C-Reactive Protein, and Procalcitonin in Patients with COVID-19. Journal of Clinical Virology. 2020; 127: 1-5.

Chen W, Zheng KI, Liu S, Yan Z, Xu C, and Qiao Z. Plasma CRP Level is Positively Associated with the Severity of COVID-19. Annals of Clinical Microbiology and Antimicrobial. 2020; 19(1): 1-7

Liu ZM, Li JP, Wang SP, et al. Association of Procalcitonin Levels with the Progression and Prognosis of Hospitalized Patients with COVID-19. International Journal of Medical Science. 2020; 17(16): 2468–2476.

Aloisio E, Dolci A, and Panteghini M. Procalcitonin: Between Evidence and Critical Issues. Clinical Chimica Acta. 2019; 496: 7–12.

Vanhomwegen C, Veliziotis I, Malinverni S, et al. Procalcitonin Accurately Predicts Mortality But Not Bacterial Infection in COVID-19 Patients Admitted to Intensive Care Unit. Irish Journal of Medical Science. 2021; 190(4): 1649–1652.

Djaharuddin I, Munawwarah S, Nurulita A, Ilyas M, Tabri NA, and Lihawa N. Comorbidities and Mortality in COVID-19 Patients. Gaceta Sanitaria. 2021; 35(2): 530–532.

Biswas M, Rahaman S, Biswas TK, Haque Z, and Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology. 2020; 64(1): 1–12.

Guo A, Lu J, Tan H, et al. Risk Factors on Admission Associated with Hospital Length of Stay in Patients with COVID-19: A Retrospective Cohort Study. Scientific Reports. 2021; 11(1): 1-7.

Alwafi H, Naser AY, Qanash S, et al. Predictors of Length of Hospital Stay, Mortality, and Outcomes among Hospitalised COVID-19 Patients in Saudi Arabia: A Cross-Sectional Study. Journal of Multidisciplinary Healthcare. 2021; 14: 839–852.

Crimmins EM. Age-Related Vulnerability to Coronavirus Disease 2019 (COVID-19): Biological, Contextual, and Policy-Related Factors. The Public Policy and Aging Report. 2020; 30(4): 142–146.

Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, and Khajuria A. The Effect of Smoking on COVID-19 Severity: A Systematic Review and Meta-Analysis. Journal of Medical Virology. 2021; 93(2): 1045–1056.

Puebla Neira D, Watts A, Seashore J, Polychronopoulou E, Kuo YF, Sharma and G. Smoking and Risk of COVID-19 Hospitalization. Respiratory Medicine. 2021; 182: 1-7.

Lippi G and Henry BM. Active Smoking is Not Associated with Severity of Coronavirus Disease 2019 (COVID-19). European Journal of Internal Medicine. 2020; 75: 107–108.

Alimohamadi Y, Sepandi M, Taghdir M, and Hosamirudsari H. Determine the Most Common Clinical Symptoms in COVID-19 Patients: A Systematic Review and Meta-Analysis. Journal of Preventive Medicine and Hygiene. 2020; 61(3): 304–312.

Hidayati D. Profil Penduduk Terkonfirmasi Positif Covid-19 dan Meninggal: Kasus Indonesia dan DKI Jakarta. Jurnal Kependudukan Indonesia. 2020; 2020: 93-100.

Rory SH, Utariani A, and Semedi BP. Analisis Faktor Risiko Oxygenation Index, Oxygen Saturation Index, dan Rasio Pao2/Fio2 sebagai Prediktor Mortalitas Pasien Pneumonia COVID-19 dengan ARDS di Ruang Perawatan Intensif Isolasi Khusus RSUD Dr Soetomo. Jurnal Anestesi Perioperatif. 2021; 9(1): 1–9.

Seeley E, McAuley DF, Eisner M, Miletin M, Matthay MA, and Kallet RH. Predictors of Mortality in Acute Lung Injury during the Era of Lung Protective Ventilation. Thorax. 2008; 63(11): 994–998.

Ahmed S, Ahmed ZA, Rashid NH, Mansoor M, Siddiqui I, and Jafri L. Procalcitonin as a Predictor of Severity and Mortality in a Cohort of Patients Hospitalised with COVID-19. The Malaysian Journal of Pathology. 2021; 43(3): 375–380.

Xu JB, Xu C, Zhang RB, et al. Associations of Procalcitonin, C-Reaction Protein and Neutrophil-to-Lymphocyte Ratio with Mortality in Hospitalized COVID-19 Patients in China. Scientific Reports. 2020; 10(1): 1-10.

Hu R, Han C, Pei S, Yin M, and Chen X. Procalcitonin Levels in COVID-19 Patients. International Journal of Antimicrobial Agents. 2020; 56(2): 1-4.

Zhang L, Hou J, Ma FZ, Li J, Xue S, and Xu ZG. The Common Risk Factors for Progression and Mortality in COVID-19 Patients: A Meta-Analysis. Archives of Virology. 2021; 166(8): 2071–2087.

Jang SY, Seon JY, Yoon SJ, Park SY, Lee SH, and Oh IH. Comorbidities and Factors Determining Medical Expenses and Length of Stay for Admitted COVID-19 Patients in Korea. Risk Management and Healthcare Policy. 2021; 14: 2021–2033.

Christanto A, Listyoko AS, and Putra NPP. Analysis of Comorbidity and Its Association with Disease Severity and Mortality Rate in Hospitalized COVID-19 Patients. Jurnal Respirologi Indonesia. 2022; 42(1): 18–25.

Downloads

Published

2024-08-30

Issue

Vol. 33 No. 2 (2024)

Section

Research Article

License

Copyright (c) 2024 Jurnal Kedokteran Brawijaya

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).